Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315754 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
A Phase 2 study of Localized Prostate Cancer, sponsored by Steba Biotech S.A..
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03315754 is a Phase 2 study of Localized Prostate Cancer that is active but no longer recruiting, run by Steba Biotech S.A.. The registered enrollment target is 50 participants, below the 109-participant average among 6 other Localized Prostate Cancer trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03315754, a Phase 2 study of Localized Prostate Cancer, is active but no longer recruiting, sponsored by Steba Biotech S.A..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. Men with localized prostate cancer will receive TOOKAD® Soluble VTP under general anesthesia. To evaluate the absence of biopsy detectable Gleason grade 4 or 5 prostate cancer tumors anywhere in the prostate gland on 12-month, post-treatment biopsy following TOOKAD® Soluble-VTP in men with prostate cancer Gleason score 7(3+4).
Conditions Studied
Interventions
- DRUG TOOKAD Soluble 4 mg/kg
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2017-10-02 |
| Est. Completion | 2025-02-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03315754
The ClinicalTrials.gov registry entry for NCT03315754 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 6 other Localized Prostate Cancer trials with a reported enrollment target (54% lower). The listed sponsor is Steba Biotech S.A., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Localized Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which TOOKAD Soluble 4 mg/kg is the first listed.
NCT03315754 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03315754 about?
NCT03315754 is a clinical study titled "Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.". Single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. Men with localized prostate cancer will receive TOOKAD® Soluble VTP under general anesthesia. To evaluate the absence of biopsy detectable Gleason grade 4 or 5 prostate cancer tumors anywhere in the prostate gland o...
What is the current status of trial NCT03315754?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2017-10-02. Estimated completion is 2025-02-02.
What conditions does trial NCT03315754 study?
This clinical trial studies the following conditions: Localized Prostate Cancer.
What interventions are being tested in trial NCT03315754?
The interventions under investigation include: TOOKAD Soluble 4 mg/kg (DRUG).
Who is sponsoring clinical trial NCT03315754?
This trial is sponsored by Steba Biotech S.A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03315754 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Localized Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
RECRUITING · Phase 2
-
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
RECRUITING · Phase 2
-
WATER IV Prostate Cancer
RECRUITING · NA
-
PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System
ACTIVE NOT RECRUITING · NA
-
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
ACTIVE NOT RECRUITING · NA
-
Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.